Search results
Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Reve
Guru Focus· 5 hours agoOn May 8, 2024, Avadel Pharmaceuticals PLC (AVDL, Financial) released its 8-K filing, announcing its financial results for the first quarter ended March 31, 2024. The specialty ...
NRx Pharmaceuticals eyes first commercial revenue in 2024, announces breakthroughs in bi-annual...
Invezz· 10 hours agoNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing...
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
New York Post· 7 hours agoBy 1988, it was the world’s best selling drug as patients reported benefits for conditions such as...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters via Yahoo Finance· 12 hours agoTeva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's...
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of...
WJET - WFXP Erie· 13 hours agoMinghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune...
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
Reuters· 12 hours agoIsrael-based Teva Pharmaceuticals , and French partner Medincell said on Wednesday their injectable...
Unveiling Vertex Pharmaceuticals (VRTX)'s Value: Is It Really Pr
Guru Focus· 5 hours agoVertex Pharmaceuticals Inc (VRTX, Financial) recently showcased a daily gain of 2.86%, despite a slight 3-month loss of 0.7%. This article delves into the intrinsic value ...
Getting In on This “Macro-Trend”
InvestorPlace· 4 hours agoThe biotech sector, in particular, is offering a compelling and timely opportunity. In fact, I made this recommendation to my Fry’s Investment Report...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics - Vertex Pharmaceuticals...
Benzinga· 4 hours agoIts key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where ...
Hong Kong attracts US$832 million in investment from life-science firms
South China Morning Post· 12 hours agoAmong the 45 companies, more than 60 per cent are in the therapeutics sector, which includes ...
